

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/29/1948  
Gender: Male  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Collection Date: 00/00/0000 00:00

Hypoglycemia Panel (Sulfonylureas), Serum or Plasma  
ARUP test code 3005636

Rosiglitazone  
None Det ng/mL  
Serum or Plasma  
Reporting Limit: 40 ng/mL  
Synonym(s): Avandia(R); Avandaryl(R); Avandamet(R)  
Peak plasma concentrations of approximately 70-430 ng/mL and 240-830 ng/mL were achieved 1 hour after administration of 4 mg and 8 mg daily doses, respectively.  
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Chlorpropamide  
None Det mcg/mL  
Serum or Plasma  
Reporting Limit: 0.10 mcg/mL  
Synonym(s): Diabinese(R)  
Peak plasma concentrations of approximately 75-360 mcg/mL were achieved 2 hours following chronic daily doses of 250-1000 mg.  
The blood to plasma ratio of chlorpropamide is not known.  
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Glimepiride  
None Det ng/mL  
Serum or Plasma  
Reporting Limit: 25 ng/mL  
Synonym(s): Duetact(R); Avandaryl(R); Amaryl(R)  
Peak plasma concentrations of approximately 60-340 ng/mL were achieved 2-3 hours after administration of 4 mg of glimepiride.  
The blood to plasma ratio of Glimepiride is not known.  
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Glipizide 330 ng/mL

H=High, L=Low, \*=Abnormal, C=Critical

	<p>Serum or Plasma Reporting Limit: 40 ng/mL</p> <p>Synonym(s): Glynase; Glucotrol(R); Glibenese Peak plasma concentrations of approximately 310-610 ng/mL were achieved after administration of a single 5 mg dose of both immediate and extended release formulations. Maximum concentrations were reached in approximately 1.5-4.5 and 3.5-7 hours after immediate and extended release dosing, respectively. The blood to plasma ratio of Glipizide is not known. Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)</p>
Pioglitazone	<p>130 ng/mL</p> <p>Serum or Plasma Reporting Limit: 40 ng/mL</p> <p>Synonym(s): Duetact(R); ActoPlus Met(R); Actos(R); Oseni(R) Peak plasma concentrations of approximately 530-2600 ng/mL were achieved 1-4 hour after administration of 45 mg of pioglitazone. Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)</p>
Glyburide	<p>None Det ng/mL</p> <p>Serum or Plasma Reporting Limit: 40 ng/mL</p> <p>Synonym(s): Prestab(R); Micronase(R); Glibenclamide; Glynase(R) Peak plasma concentrations of approximately 130-200 ng/mL following a single 5 mg dose have been reported. A group of ten diabetic patients given daily oral 2.5 mg doses for 6 weeks attained peak plasma glyburide concentrations averaging 140 ng/mL at 3 hours after the first dose and 240 ng/mL at 2.4 hours after the last dose. Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)</p>
Nateglinide	<p>None Det mcg/mL</p> <p>Serum or Plasma Reporting Limit: 0.10 mcg/mL</p> <p>Synonym(s): Starlix(R) Peak plasma concentrations of approximately 1.3-7.5 mcg/mL were achieved 0.5 hours following a single 60 mg dose. Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)</p>
Tolazamide	<p>None Det mcg/mL</p>
<p><b>H=High, L=Low, *=Abnormal, C=Critical</b></p>	

Serum or Plasma  
Reporting Limit: 0.10 mcg/mL  
  
Synonym(s): Tolinase(R)  
No plasma concentrations have been reported in the literature  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**Tolbutamide**

None Det mcg/mL  
Serum or Plasma  
Reporting Limit: 0.10 mcg/mL  
  
Synonym(s): Orinase(R)  
Peak plasma concentrations of approximately 50-100 mcg/mL were achieved 3-5 hours following chronic daily doses.  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

**Repaglinide**

None Det ng/mL  
Serum or Plasma  
Reporting Limit: 10 ng/mL  
  
Synonym(s): Prandin(R); PrandiMet(R)  
Peak plasma concentrations of approximately <10-180 ng/mL were achieved 1 hour after administration of 4 mg of repaglinide.  
Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)  
This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.  
Digital data review may have taken place remotely by qualified NMS staff utilizing a secure VPN connection for some or all of the reported results. This is in accordance with and follows CLIA regulations.  
Testing performed at NMS Labs, Inc.  
200 Welsh Road  
Horsham, PA 19044-2208  
CLIA 39D0197898

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Rosiglitazone	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Chlorpropamide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glimepiride	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glipizide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Pioglitazone	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Glyburide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Nateglinide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tolazamide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Tolbutamide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Repaglinide	24-155-110257	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical